Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model

Citation
Nc. Lee et al., Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model, CLIN EXP M, 18(5), 2001, pp. 379-384
Citations number
20
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
CLINICAL & EXPERIMENTAL METASTASIS
ISSN journal
0262-0898 → ACNP
Volume
18
Issue
5
Year of publication
2001
Pages
379 - 384
Database
ISI
SICI code
0262-0898(2001)18:5<379:AEOAGI>2.0.ZU;2-X
Abstract
Gemcitabine is a promising new agent that has been recently studied for pal liation of advanced (stage IV) unresectable pancreatic cancer. We hypothesi zed that adjuvant gemcitabine would reduce recurrence and metastases follow ing surgical resection of pancreatic cancer. To test this hypothesis, we ev aluated gemcitabine on a green fluorescent protein (GFP) transductant of th e human pancreatic cancer cell line BxPC-3 (BxPC-3-GFP) using surgical orth otopic implantation (SOI) in nude mice. GFP enabled high resolution fluores cent visualization of primary and metastatic growth. Five weeks after SOI, the mice were randomized into three groups: Group I received exploratory la parotomy only. Group II underwent surgical resection of the pancreatic tumo r without further treatment. Group III underwent tumor resection followed b y adjuvant treatment with gemcitabine, 100 mg/kg every three days for a tot al of four doses, starting two days after resection. The mice were sacrific ed at thirteen weeks following implantation and the presence and location o f recurrent tumor was recorded. Gemcitabine reduced the recurrence rate to 28.6% compared to 70.6% with resection only (P=0.02) and reduced metastatic events 58% in the adjuvant group compared to resection only. This study, d emonstrating that gemcitabine is effective as adjuvant chemotherapy post-pa ncreatectomy, suggests this new indication of the drug clinically.